Pluvicto Market By Indication (Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Castration-Sensitive Prostate Cancer (mCSPC), Advanced PSMA-Positive Prostate Cancer), By Line of Therapy (First-Line Therapy, Second-Line Therapy, Third-Line and Later Therapy), By Route of Administration (Intravenous (IV), Intramuscular (IM)), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies, Retail Pharmacies), By End-User (Hospitals, Specialty Cancer Clinics, Radiotherapy Centers, Academic and Research Institutes, Diagnostic Imaging Centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Indication

• Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• Advanced PSMA-Positive Prostate Cancer

By Line of Therapy

• First-Line Therapy
• Second-Line Therapy
• Third-Line and Later Therapy

By Route of Administration

• Intravenous (IV)
• Intramuscular (IM)

By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies
• Retail Pharmacies

By End-User

• Hospitals
• Specialty Cancer Clinics
• Radiotherapy Centers
• Academic and Research Institutes
• Diagnostic Imaging Centers

By Region

North America

• The U.S.
• Canada

Europe

• Germany
• France
• U.K.
• Italy
• Spain

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea

Latin America

• Brazil
• Argentina
• Mexico

MEA

• Saudi Arabia
• United Arab Emirates
• South Africa

List of Companies

• Novartis
• Bayer
• Lantheus Medical Imaging
• Cardinal Health
• GE Healthcare
• Siemens Healthineers
• Astellas Pharma
• Eli Lilly and Company
• Ipsen
• Merck Group